What question did this study set out to answer?

This research aims to investigate the binding properties of palladium(II) complexes with DNA and BSA.

March 1, 2026

DNA-and BSA-binding properties of dichloro(1-methallyl-3-arylmethyl-5,6-dimethylbenzimidazolin-2-ylidene)pyridine palladium(II) complexes.

Key Points

This research aims to investigate the binding properties of palladium(II) complexes with DNA and BSA.
Experimental evaluation of binding constants for palladium(II) complexes 2a and 2c
Molecular docking analysis to assess interactions with DNA and BSA residues
Evaluation of drug-likeness properties using the SwissADME web tool.
Complex 2a showed the highest DNA binding constant (1.84 × 10^4 M^-1)
Complex 2c demonstrated the highest BSA binding constant (2.83 × 10^4 M^-1)
Molecular docking confirmed strong interactions of both complexes with DNA and BSA residues.

Abstract

According to the experimental method, complex 2a exhibited the strongest binding constant against DNA (1.84 × 104 M-1), while complex 2c demonstrated the highest BSA binding constant (2.83 × 104 M-1). Subsequent to molecular docking, and consistent with experimental findings, it was determined that all molecules exhibited interaction with the same DNA and BSA residues. Complex 2a demonstrated the strongest binding affinity against DNA, while complex 2c manifested the most robust interaction with a binding value of -8.09 kcal/mol. A thorough evaluation of the drug-likeness properties of the palladium(II) complexes was conducted using the SwissADME web tool.

KI fragen

Bookmark

View Full Paper

Cite This Study

Üstün et al. (Thu,) studied this question.

synapsesocial.com/papers/69a3d887ec16d51705d2f77a https://doi.org/https://doi.org/10.1080/17568919.2026.2636820

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper